GH Research (NASDAQ:GHRS) Stock Price Up 3.8% – What’s Next?

GH Research PLC (NASDAQ:GHRS) rose 3.8% during trading on Wednesday . The stock traded as high as $9.60 and last traded at $9.50. Approximately 9,127 shares changed hands during trading, a decline of 88% from the average daily volume of 79,000 shares. The stock had previously closed at $9.15.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on GHRS shares. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Thursday, September 5th. JMP Securities restated a “market outperform” rating and set a $39.00 price target on shares of GH Research in a report on Wednesday, September 4th.

GH Research Trading Up 1.4 %

The business has a 50-day moving average of $7.72 and a 200-day moving average of $10.40.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. Analysts predict that GH Research PLC will post -0.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP lifted its holdings in GH Research PLC (NASDAQ:GHRS) by 80.1% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,310,563 shares of the company’s stock after purchasing an additional 1,471,946 shares during the period. GH Research makes up 9.1% of Lynx1 Capital Management LP’s holdings, making the stock its 6th biggest holding. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).